```html

Zollinger‑Ellison Syndrome (Gastric Acid Hypersecretion) – A Patient‑Friendly Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors called gastrinomas form in the pancreas or duodenum. These tumors secrete excessive amounts of the hormone gastrin, which in turn stimulates the stomach lining to produce large volumes of acid. The resulting gastric acid hypersecretion leads to severe peptic ulcer disease, diarrhea, and a cascade of other gastrointestinal problems.

• Prevalence: Approximately 0.5–2 cases per million people worldwide. About 20–25 % of cases are associated with the inherited condition multiple endocrine neoplasia type 1 (MEN 1).<sup>1</sup>
• Typical age of onset: Most patients are diagnosed between 30 and 60 years of age, though it can occur at any age.
• Gender: Slight male predominance (≈55 % male).

Symptoms

Because excess acid attacks the lining of the gastrointestinal (GI) tract, symptoms can be wide‑ranging. Not every patient will have all of them, and severity may fluctuate.

Digestive symptoms

• Recurrent, painful ulcers – usually multiple and located beyond the duodenal bulb (duodenal, jejunal, or even colonic ulcers).
• Abdominal pain – cramping or burning pain that may improve temporarily after eating (due to buffering by food) but returns later.
• Diarrhea – often watery, sometimes steatorrheic (fatty) because acid inactivates pancreatic enzymes.
• Steatorrhea – foul‑smelling, greasy stools caused by malabsorption of fats.
• Nausea / vomiting – may be triggered by ulcer pain or by the massive acid load.
• Gastroesophageal reflux disease (GERD) – heartburn that is refractory to over‑the‑counter antacids.

Systemic symptoms

• Weight loss – secondary to malabsorption and chronic diarrhea.
• Fatigue – from anemia (often iron‑deficiency due to chronic bleeding) or from chronic disease.
• Dehydration & electrolyte disturbances – especially low potassium (hypokalemia) from watery diarrhea.

Signs that may suggest an associated MEN 1 syndrome

• Hyperparathyroidism (high calcium levels)
• Pituitary adenoma (headaches, visual changes)
• Family history of endocrine tumors

Causes and Risk Factors

Primary cause

ZES is caused by gastrin‑producing neuroendocrine tumors (gastrinomas). Roughly 80 % are sporadic, while 20–25 % occur as part of MEN 1, a genetic mutation in the MEN1 tumor suppressor gene.

Risk factors

• MEN 1 inheritance – autosomal‑dominant; first‑degree relatives have a 50 % chance of carrying the mutation.<sup>2</sup>
• Family history of gastrinomas – even without full MEN 1, a hereditary predisposition can increase risk.
• Age – risk rises after the third decade of life.
• Chronic gastritis or Helicobacter pylori infection – does not cause ZES but can mask its symptoms, delaying diagnosis.

Diagnosis

Because ZES mimics common ulcer disease, a high index of suspicion is essential. Diagnosis combines biochemical testing, imaging, and endoscopic evaluation.

Biochemical tests

• Fasting serum gastrin level – values > 1000 pg/mL are highly suggestive; levels 2–10 × upper limit of normal with a gastric pH < 2 are diagnostic.<sup>3</sup>
• Secretin stimulation test – after IV secretin, gastrin rises > 200 pg/mL in ZES (paradoxical response).
• Serum calcium & parathyroid hormone – to screen for MEN 1.

Endoscopic evaluation

• Upper endoscopy (EGD) – identifies multiple ulcers, assesses bleeding, and allows biopsy to rule out malignancy.
• Capsule endoscopy or double‑balloon enteroscopy – visualizes distal small‑bowel ulcers that are otherwise missed.

Imaging for tumor localization

• Contrast‑enhanced CT (pancreas protocol) or MRI – first‑line cross‑sectional imaging.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – highly sensitive for neuroendocrine tumors.
• EUS (endoscopic ultrasound) – excellent for detecting small pancreatic lesions (< 1 cm).

Pathology

If surgery is performed, the tumor is examined for size, mitotic index, and Ki‑67 proliferative index to stage disease and guide follow‑up.

Treatment Options

Medical management – controlling acid hypersecretion

1. Proton‑pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole are first‑line. Doses may be 3–5 times the standard ulcer regimen; titration is guided by symptom control and gastrin levels.<sup>4</sup>
2. H2‑receptor antagonists – famotidine or ranitidine (if available) can be added for breakthrough symptoms, but PPIs are superior.
3. Octreotide (somatostatin analog) – reduces gastrin secretion and can shrink small gastrinomas, especially in MEN 1 patients.

Surgical intervention

• Localized gastrinoma – enucleation or pancreaticoduodenectomy (Whipple) when the tumor is resectable.
• Multiple or metastatic disease – debulking surgery plus targeted therapies (e.g., everolimus, sunitinib) and liver-directed treatments (radiofrequency ablation, embolization).

Targeted systemic therapy

• Everolimus – mTOR inhibitor approved for advanced pancreatic neuroendocrine tumors.
• Sunitinib – tyrosine‑kinase inhibitor with activity against neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE for somatostatin‑receptor positive disease.

Lifestyle and supportive measures

• Small, frequent meals to buffer acid.
• Avoidance of alcohol, caffeine, nicotine, and non‑steroidal anti‑inflammatory drugs (NSAIDs) that aggravate ulcers.
• Supplementation with calcium, vitamin D, and iron if deficiencies develop.
• Hydration and electrolyte monitoring, especially if diarrhea is prominent.

Living with Zollinger‑Ellison Syndrome (Gastric Acid Hypersecretion)

Daily medication routine

1. Take PPIs on an empty stomach, usually 30 minutes before breakfast; maintain the exact dose prescribed.
2. If on octreotide, follow the injection schedule (often subcutaneous twice daily or long‑acting depot every 4 weeks).
3. Keep a medication diary to note any breakthrough symptoms or side effects.

Nutrition tips

• Eat low‑fat, low‑spice meals; fat can delay gastric emptying and worsen reflux.
• Incorporate soluble fiber (e.g., oats, applesauce) to help bulk stools.
• Consider probiotic supplements to support gut flora altered by chronic acid suppression.

Monitoring & follow‑up

• Quarterly serum gastrin and calcium levels (more often if MEN 1).
• Annual imaging (CT or MRI) to detect tumor recurrence or metastasis.
• Regular endoscopy (every 1–2 years) to assess ulcer healing.

Psychosocial aspects

Living with a chronic rare disease can be stressful. Join support groups (e.g., NEC Network) and consider counseling to cope with anxiety or depression.

Prevention

Since ZES is largely driven by tumor biology, true primary prevention is limited. However, risk reduction strategies include:

• Genetic counseling for families with known MEN 1 mutations; early screening can detect gastrinomas before they become symptomatic.
• Avoidance of known ulcer‑aggravating agents (NSAIDs, smoking, heavy alcohol) to prevent secondary complications.
• Prompt treatment of H. pylori infection – while it does not cause ZES, eradicating it reduces background ulcer burden and diagnostic confusion.

Complications

If untreated or poorly controlled, excessive gastric acid can lead to serious health problems:

• Perforated peptic ulcer – emergency surgery required.
• Bleeding ulcer – may cause anemia or life‑threatening hemorrhage.
• Gastrointestinal strictures – from chronic ulcer scarring, causing obstruction.
• Malabsorption syndrome – fat‑soluble vitamin deficiencies (A, D, E, K) and weight loss.
• Metastatic disease – approximately 60–80 % of gastrinomas are malignant at diagnosis, most commonly spreading to the liver and lymph nodes.<sup>5</sup>
• Refractory GERD and Barrett’s esophagus – long‑term acid exposure increases esophageal cancer risk.

When to Seek Emergency Care

---

References:
1. Mayo Clinic. “Zollinger‑Ellison syndrome.” mayoclinic.org.
2. Gjerde, P. et al. “MEN1 genotype–phenotype correlations.” Endocrine Reviews, 2014.
3. CDC Rare Diseases. “Zollinger‑Ellison Syndrome.” cdc.gov.
4. Cleveland Clinic. “Zollinger‑Ellison Syndrome Treatment.” clevelandclinic.org.
5. Liu, H. et al. “Management of Gastrinomas and Neuroendocrine Tumors.” Journal of Clinical Oncology, 2020.

```